Sequential trial with B method of Potvin [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2015-10-01 19:58 (3420 d 03:54 ago) – Posting: # 15514
Views: 11,606

Hi JJ,

❝ In a sequential clinical trial conducted like a B method of Potvin, we have Cmax and AUC both not bioequivalent. Cmax has a power <80% (71.5%), and AUC>80% (84.6%).

❝ AUC 0-30min calculated by protocol is bioequivalent.

❝ In the protocol it was not specified how to proceed in this situation.


❝ Can we calculate a new n and pass to the second phase? Or we must stop the trial?


I would go by the metric that displays the highest variance, which is usually Cmax. I suggest to proceed towards stage 2 on that basis.
However, since this was not pre-specified it is your protocol that document may be your biggest issue now; regulators may not like whatever decision you take.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,379 posts in 4,913 threads, 1,661 registered users;
254 visitors (0 registered, 254 guests [including 21 identified bots]).
Forum time: 22:52 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5